Lifeboat Foundation

An experimental cancer-killing virus has been administered to a human patient for the first time, with hopes the testing will ultimately reveal evidence of a new means of successfully fighting cancer tumors in people’s bodies.

The drug candidate, called CF33-hNIS (aka Vaxinia), is what’s called an oncolytic virus, a genetically modified virus designed to selectively infect and kill cancer cells while sparing healthy ones.

In the case of CF33-hNIS, the modified pox virus works by entering cells and duplicating itself. Eventually, the infected cell bursts, releasing thousands of new virus particles that act as antigens, stimulating the immune system to attack nearby cancer cells.

Staphylococcus aureus infections can be highly unpredictable – some cause a slight rash, whereas others can lead to deadly complications – and researchers have identified a genetic mutation that could be the cause of these differences.

A mechanism that causes autism, schizophrenia, Alzheimer’s and other conditions and is shared by mutations in the genes ADNP and SHANK3 has been unraveled by Tel Aviv University researchers who developed an experimental drug they found to be effective in animal models.

The drug could also be suitable for treating a range of rare syndromes that impair brain functions, said the scientists. The researchers were led by Prof. Illana Gozes from the Department of Human Molecular Genetics and Biochemistry at TAU’s Sackler Faculty of Medicine and the Sagol School of Neuroscience. The experimental drug, called Davunetide, had previously been developed in her lab.

The paper, which the team called a “scientific breakthrough,” was published in the scientific journal Molecular Psychiatry under the title “SH3-and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.”

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Levine’s Biological age calculator is embedded as an Excel file in this link from my website:
https://michaellustgarten.com/2019/09/09/quantifying-biological-age/

Continue reading “Quantifying Biological Age: Blood Test #3 in 2022” »

In this episode of Longevity by Design, our hosts, Dr. Gil Blander and Ashley Reaver, MS, RD, CSSD, are joined by Dr. George Church, Professor of Genetics at Harvard Medical School. Tune in as Dr. George Church discusses the many roles of gene therapy, including its ability to reverse age-related diseases.

For science-backed ways to live a healthier, longer life, download InsideTracker’s InnerAge eBook at insidetracker.com/podcast.

Continue reading “Dr. George Church—Gene Therapy and Aging” »

During that uncomfortable period between puberty and adulthood, the brain undergoes carefully orchestrated changes in gene expression and epigenetic modification. Alcohol, unfortunately, interferes with this biological architecture. Consequently, mistakes are made, and gene expression and modification do not go as planned, leaving the person vulnerable to a lifetime of psychiatric challenges, such as anxiety and alcoholism.

A team of researchers from the University of Illinois Chicago recently found they could reverse these changes in rats via gene editing. If their findings carry through to human studies, gene editing may be a potential treatment for anxiety and alcohol-use disorder in adults who were exposed to binge drinking in their adolescence.

Summary: Researchers used optogenetics techniques to stimulate specific brain areas to increase neurogenesis and the production of neural stem cells to improve memory, cognition, and emotional processing in animal models.

Source: UNC Health Care.

We humans lose mental acuity, an unfortunate side effect of aging. And for individuals with neurodegenerative conditions such as Alzheimer’s and Parkinson’s, the loss of cognitive function often accompanied by mood disorders such as anxiety is a harrowing experience. One way to push back against cognitive decline and anxiety would be to spur the creation of new neurons.

In a few months, a daring clinical trial may fundamentally lower heart attack risk in the most vulnerable people. If all goes well, it will just take one shot.

It’s no ordinary shot. The trial, led by Verve Therapeutics, a biotechnology company based in Massachusetts, will be one of the first to test genetic base editors directly inside the human body. A variant of the gene editing tool CRISPR-Cas9, base editors soared to stardom when first introduced for their efficiency at replacing single genetic letters without breaking delicate DNA strands. Because it’s safer than the classic version of CRISPR, the new tool ignited hope that it could be used for treating genetic diseases.

Verve’s CEO, Dr. Sekar Kathiresan, took note. A cardiologist at Harvard University, Kathiresan wondered if base editing could help solve one of the main killers of our time: heart attacks. It seemed the perfect test case. We know one major cause of heart attacks—high cholesterol levels, particularly a version called LDL-C (Low-density lipoprotein cholesterol). We also know several major genes that control its level. And—most importantly—we know the DNA letter swap that can, in theory, drastically lower LDL-C and in turn throttle the risk of heart attacks.

In biological evolution, we know that it’s all about the survival of the fittest: organisms that develop genetic traits that allow them to better adapt to their physical environment are more likely to thrive, and thus pass down their winning genes to their offspring.

From the longer-beaked Galapagos Island finches studied by biologist Charles Darwin that enabled them to more effectively snatch insects, to the ability of some humans over others to digest milk, the process of natural selection results in genetic differences that give some organisms an edge over others.

New research by University of Toronto Mississauga biology assistant professor Alex N. Nguyen Ba adds an important dimension to our understanding of how genes interact in the evolutionary process.